Current Report Filing (8-k)
August 18 2020 - 4:57PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event
reported): August 18, 2020
ALBIREO PHARMA, INC.
(Exact name of registrant as specified in
its charter)
Delaware
(State or other jurisdiction of
incorporation)
|
|
001-33451
(Commission File
Number)
|
|
90-0136863
(IRS Employer
Identification No.)
|
10 Post Office Square, Suite 502 South
Boston, Massachusetts
(Address of principal executive offices)
|
|
02109
(Zip Code)
|
(857) 254-5555
Registrant’s telephone number, including
area code
Not applicable
(Former name or former address, if changed
since last report)
Check the appropriate box below if the Form 8-K filing
is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
¨
|
Written communications pursuant to Rule 425 under
the Securities Act (17 CFR 230.425)
|
¨
|
Soliciting material pursuant to Rule 14a-12 under
the Exchange Act (17 CFR 240.14a-12)
|
¨
|
Pre-commencement communications pursuant to Rule 14d-2(b) under
the Exchange Act (17 CFR 240.14d-2(b))
|
¨
|
Pre-commencement communications pursuant to Rule 13e-4(c) under
the Exchange Act (17 CFR 240.13e-4(c))
|
Securities registered pursuant to Section 12(b) of
the Act:
Title of each class
|
|
Trading Symbol(s)
|
|
Name of each exchange on which
registered
|
|
Common Stock
|
|
ALBO
|
|
The Nasdaq Capital Market
|
|
Indicate by check mark whether the registrant is an emerging
growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of
the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging
growth company ¨
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for
complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange
Act. ¨
Item 8.01 Other Events.
On August 18,
2020, Albireo Pharma, Inc. issued a press release announcing topline results from the Phase 2 proof-of-concept clinical trial evaluating elobixibat, its ileal bile acid transporter (IBAT) inhibitor
currently approved in Japan for chronic constipation, for the treatment of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis
(NASH). A copy of the press release is attached
hereto as Exhibit 99.1 and is incorporated herein by reference.
Item 9.01 Financial Statements and Exhibits.
SIGNATURES
Pursuant to the requirements of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
ALBIREO PHARMA, INC.
|
|
|
|
|
Date: August 18, 2020
|
/s/ Ronald
H.W. Cooper
|
|
Ronald H.W. Cooper
|
|
President and Chief Executive Officer
|
Albireo Pharma (NASDAQ:ALBO)
Historical Stock Chart
From Mar 2024 to Apr 2024
Albireo Pharma (NASDAQ:ALBO)
Historical Stock Chart
From Apr 2023 to Apr 2024